| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Osteoarthritis, Knee | 117 | 2026 | 395 | 26.300 |
Why?
|
| Knee Joint | 68 | 2026 | 310 | 11.580 |
Why?
|
| Osteoarthritis | 23 | 2026 | 146 | 7.990 |
Why?
|
| Disease Progression | 43 | 2026 | 1210 | 6.040 |
Why?
|
| Cartilage, Articular | 19 | 2024 | 79 | 4.740 |
Why?
|
| Radiography | 31 | 2026 | 556 | 4.200 |
Why?
|
| Arthroplasty, Replacement, Knee | 9 | 2023 | 134 | 4.150 |
Why?
|
| Hand Joints | 11 | 2026 | 23 | 4.120 |
Why?
|
| Arthralgia | 13 | 2024 | 58 | 3.830 |
Why?
|
| Knee Injuries | 13 | 2026 | 49 | 3.730 |
Why?
|
| Anterior Cruciate Ligament Injuries | 15 | 2024 | 34 | 3.330 |
Why?
|
| Bone Marrow | 10 | 2020 | 176 | 3.310 |
Why?
|
| Synovitis | 7 | 2022 | 30 | 3.300 |
Why?
|
| Magnetic Resonance Imaging | 34 | 2024 | 2238 | 2.740 |
Why?
|
| Anterior Cruciate Ligament Reconstruction | 12 | 2024 | 27 | 2.660 |
Why?
|
| Aged | 85 | 2026 | 14843 | 2.390 |
Why?
|
| Middle Aged | 100 | 2026 | 18115 | 2.390 |
Why?
|
| Pain Measurement | 21 | 2024 | 340 | 2.230 |
Why?
|
| Male | 129 | 2026 | 30809 | 2.180 |
Why?
|
| Tibia | 14 | 2023 | 75 | 2.040 |
Why?
|
| Female | 127 | 2026 | 33762 | 2.020 |
Why?
|
| Humans | 168 | 2026 | 64770 | 2.020 |
Why?
|
| Longitudinal Studies | 27 | 2024 | 1274 | 1.970 |
Why?
|
| Menisci, Tibial | 5 | 2024 | 28 | 1.940 |
Why?
|
| Exercise | 16 | 2025 | 959 | 1.770 |
Why?
|
| Severity of Illness Index | 20 | 2024 | 1556 | 1.760 |
Why?
|
| Cartilage Diseases | 3 | 2022 | 12 | 1.670 |
Why?
|
| Risk Factors | 32 | 2024 | 5399 | 1.600 |
Why?
|
| Case-Control Studies | 18 | 2026 | 1135 | 1.430 |
Why?
|
| Rheumatology | 2 | 2024 | 69 | 1.390 |
Why?
|
| Exercise Therapy | 5 | 2024 | 103 | 1.380 |
Why?
|
| Cross-Sectional Studies | 31 | 2025 | 2679 | 1.350 |
Why?
|
| Carpometacarpal Joints | 2 | 2022 | 9 | 1.310 |
Why?
|
| Tibial Meniscus Injuries | 3 | 2024 | 15 | 1.260 |
Why?
|
| Gardening | 2 | 2025 | 4 | 1.160 |
Why?
|
| Joint Instability | 2 | 2019 | 57 | 1.140 |
Why?
|
| Pain | 10 | 2024 | 398 | 1.140 |
Why?
|
| Tai Ji | 12 | 2019 | 28 | 1.120 |
Why?
|
| Running | 6 | 2018 | 84 | 1.100 |
Why?
|
| Fluorocarbons | 2 | 2026 | 50 | 1.080 |
Why?
|
| Quality of Life | 11 | 2024 | 1254 | 0.940 |
Why?
|
| Walking Speed | 4 | 2020 | 24 | 0.880 |
Why?
|
| Walking | 8 | 2022 | 241 | 0.880 |
Why?
|
| Self Report | 6 | 2020 | 390 | 0.860 |
Why?
|
| Body Mass Index | 11 | 2020 | 885 | 0.860 |
Why?
|
| Synovial Fluid | 3 | 2014 | 29 | 0.860 |
Why?
|
| Knee | 4 | 2015 | 40 | 0.860 |
Why?
|
| Time Factors | 18 | 2024 | 3753 | 0.850 |
Why?
|
| Logistic Models | 10 | 2026 | 1268 | 0.840 |
Why?
|
| Bicycling | 1 | 2024 | 20 | 0.830 |
Why?
|
| Bone Density | 7 | 2024 | 142 | 0.830 |
Why?
|
| Anterior Cruciate Ligament | 3 | 2019 | 22 | 0.820 |
Why?
|
| Follow-Up Studies | 14 | 2020 | 2483 | 0.820 |
Why?
|
| Resistance Training | 1 | 2023 | 22 | 0.810 |
Why?
|
| Adrenal Cortex Hormones | 3 | 2020 | 181 | 0.800 |
Why?
|
| Femur | 10 | 2023 | 55 | 0.800 |
Why?
|
| Incidence | 13 | 2026 | 1410 | 0.780 |
Why?
|
| Sexual and Gender Minorities | 1 | 2024 | 74 | 0.750 |
Why?
|
| Football | 2 | 2020 | 17 | 0.750 |
Why?
|
| Cohort Studies | 14 | 2026 | 2603 | 0.740 |
Why?
|
| Quadriceps Muscle | 3 | 2016 | 14 | 0.730 |
Why?
|
| Chiroptera | 1 | 2022 | 17 | 0.720 |
Why?
|
| Muscle, Skeletal | 5 | 2019 | 765 | 0.710 |
Why?
|
| Metacarpophalangeal Joint | 3 | 2023 | 10 | 0.680 |
Why?
|
| Physical Therapy Modalities | 7 | 2018 | 46 | 0.670 |
Why?
|
| Prevalence | 10 | 2025 | 1434 | 0.630 |
Why?
|
| Athletic Injuries | 3 | 2017 | 84 | 0.610 |
Why?
|
| Posterior Cruciate Ligament | 1 | 2019 | 3 | 0.610 |
Why?
|
| Ligaments, Articular | 1 | 2019 | 18 | 0.600 |
Why?
|
| Synovial Membrane | 1 | 2019 | 21 | 0.590 |
Why?
|
| Weight-Bearing | 3 | 2016 | 36 | 0.580 |
Why?
|
| Fibromyalgia | 4 | 2021 | 15 | 0.570 |
Why?
|
| Prospective Studies | 15 | 2024 | 3299 | 0.570 |
Why?
|
| Homeostasis | 2 | 2018 | 378 | 0.550 |
Why?
|
| Models, Theoretical | 1 | 2019 | 274 | 0.530 |
Why?
|
| Glucose Metabolism Disorders | 1 | 2017 | 4 | 0.520 |
Why?
|
| Age Factors | 6 | 2024 | 1580 | 0.510 |
Why?
|
| Biomarkers | 8 | 2024 | 1467 | 0.510 |
Why?
|
| Bone Malalignment | 1 | 2016 | 3 | 0.500 |
Why?
|
| Adipose Tissue | 1 | 2019 | 299 | 0.490 |
Why?
|
| Meniscectomy | 1 | 2016 | 1 | 0.490 |
Why?
|
| Adult | 28 | 2024 | 17239 | 0.460 |
Why?
|
| Musculoskeletal Pain | 1 | 2015 | 26 | 0.460 |
Why?
|
| Patient Outcome Assessment | 1 | 2015 | 56 | 0.450 |
Why?
|
| Linear Models | 7 | 2019 | 406 | 0.450 |
Why?
|
| Risk Assessment | 4 | 2019 | 2091 | 0.440 |
Why?
|
| Anti-Inflammatory Agents | 2 | 2017 | 165 | 0.440 |
Why?
|
| Paracentesis | 1 | 2014 | 12 | 0.440 |
Why?
|
| Glucose | 1 | 2018 | 476 | 0.440 |
Why?
|
| Retrospective Studies | 9 | 2025 | 6811 | 0.430 |
Why?
|
| Body Weight | 1 | 2016 | 375 | 0.430 |
Why?
|
| Prognosis | 5 | 2023 | 1773 | 0.420 |
Why?
|
| Blood Glucose | 1 | 2017 | 495 | 0.420 |
Why?
|
| Finger Joint | 2 | 2024 | 13 | 0.420 |
Why?
|
| Range of Motion, Articular | 4 | 2018 | 113 | 0.410 |
Why?
|
| Overweight | 1 | 2015 | 253 | 0.400 |
Why?
|
| United States | 15 | 2021 | 8050 | 0.390 |
Why?
|
| Hyaluronic Acid | 3 | 2018 | 70 | 0.380 |
Why?
|
| Patient Reported Outcome Measures | 6 | 2022 | 160 | 0.370 |
Why?
|
| Self Medication | 1 | 2012 | 13 | 0.370 |
Why?
|
| Nonprescription Drugs | 1 | 2012 | 17 | 0.370 |
Why?
|
| Osteoarthritis, Hip | 1 | 2012 | 26 | 0.360 |
Why?
|
| Hip Joint | 1 | 2012 | 37 | 0.360 |
Why?
|
| Hyaline Cartilage | 1 | 2011 | 4 | 0.360 |
Why?
|
| Odds Ratio | 4 | 2020 | 755 | 0.350 |
Why?
|
| Bone Marrow Diseases | 1 | 2011 | 14 | 0.350 |
Why?
|
| Analgesics | 1 | 2012 | 102 | 0.340 |
Why?
|
| Reproducibility of Results | 8 | 2024 | 1689 | 0.340 |
Why?
|
| Ibuprofen | 1 | 2011 | 17 | 0.340 |
Why?
|
| Arthritis, Experimental | 1 | 2011 | 30 | 0.340 |
Why?
|
| Depression | 5 | 2019 | 889 | 0.340 |
Why?
|
| Wrist Joint | 1 | 2011 | 26 | 0.330 |
Why?
|
| Matrix Metalloproteinases | 1 | 2010 | 17 | 0.330 |
Why?
|
| Young Adult | 20 | 2024 | 4773 | 0.330 |
Why?
|
| Thumb | 2 | 2022 | 27 | 0.330 |
Why?
|
| Military Personnel | 2 | 2026 | 108 | 0.330 |
Why?
|
| Treatment Outcome | 13 | 2020 | 5764 | 0.320 |
Why?
|
| Diet | 2 | 2026 | 534 | 0.310 |
Why?
|
| Anxiety | 3 | 2019 | 422 | 0.310 |
Why?
|
| Dietary Supplements | 1 | 2012 | 234 | 0.310 |
Why?
|
| Injections, Intra-Articular | 5 | 2020 | 52 | 0.290 |
Why?
|
| Self Efficacy | 3 | 2019 | 201 | 0.280 |
Why?
|
| Viscosupplements | 2 | 2018 | 14 | 0.270 |
Why?
|
| Tibial Nerve | 1 | 2007 | 3 | 0.270 |
Why?
|
| Ultrasonography | 5 | 2022 | 489 | 0.270 |
Why?
|
| Soccer | 3 | 2015 | 13 | 0.270 |
Why?
|
| Electric Stimulation | 1 | 2007 | 139 | 0.260 |
Why?
|
| Secondary Prevention | 3 | 2023 | 163 | 0.260 |
Why?
|
| Mindfulness | 2 | 2019 | 70 | 0.260 |
Why?
|
| Hand | 2 | 2024 | 76 | 0.250 |
Why?
|
| Cartilage | 2 | 2017 | 35 | 0.250 |
Why?
|
| ROC Curve | 2 | 2017 | 292 | 0.250 |
Why?
|
| Cytokines | 1 | 2010 | 953 | 0.250 |
Why?
|
| Decanoic Acids | 1 | 2026 | 4 | 0.240 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 3 | 2022 | 202 | 0.240 |
Why?
|
| Alkanesulfonic Acids | 1 | 2026 | 10 | 0.240 |
Why?
|
| Metabolome | 1 | 2026 | 36 | 0.240 |
Why?
|
| Muscle Strength | 2 | 2016 | 39 | 0.240 |
Why?
|
| Patient Education as Topic | 2 | 2024 | 481 | 0.240 |
Why?
|
| Skin | 2 | 2017 | 415 | 0.240 |
Why?
|
| Weight Loss | 3 | 2024 | 274 | 0.240 |
Why?
|
| Sodium Chloride | 2 | 2017 | 65 | 0.230 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 4 | 2016 | 450 | 0.230 |
Why?
|
| Glucocorticoids | 2 | 2017 | 189 | 0.230 |
Why?
|
| Adolescent | 11 | 2024 | 6290 | 0.230 |
Why?
|
| Surveys and Questionnaires | 5 | 2024 | 2754 | 0.230 |
Why?
|
| Denmark | 1 | 2024 | 18 | 0.220 |
Why?
|
| Absorptiometry, Photon | 5 | 2018 | 76 | 0.220 |
Why?
|
| Azithromycin | 1 | 2023 | 34 | 0.200 |
Why?
|
| Macrolides | 1 | 2023 | 37 | 0.200 |
Why?
|
| Single-Blind Method | 6 | 2018 | 142 | 0.200 |
Why?
|
| Collagen | 2 | 2016 | 134 | 0.190 |
Why?
|
| Lower Extremity | 2 | 2022 | 160 | 0.190 |
Why?
|
| Tramadol | 1 | 2022 | 14 | 0.190 |
Why?
|
| Weight Gain | 1 | 2024 | 166 | 0.190 |
Why?
|
| Athletes | 2 | 2016 | 109 | 0.180 |
Why?
|
| Collagen Type II | 3 | 2016 | 12 | 0.180 |
Why?
|
| Machine Learning | 1 | 2024 | 192 | 0.180 |
Why?
|
| Sex Characteristics | 2 | 2017 | 211 | 0.180 |
Why?
|
| Gait | 2 | 2020 | 121 | 0.170 |
Why?
|
| Environmental Pollutants | 1 | 2022 | 97 | 0.170 |
Why?
|
| Reference Values | 2 | 2020 | 328 | 0.170 |
Why?
|
| Posture | 2 | 2011 | 127 | 0.170 |
Why?
|
| Arthroscopy | 1 | 2020 | 32 | 0.160 |
Why?
|
| Inflammation | 3 | 2024 | 1187 | 0.160 |
Why?
|
| Algorithms | 2 | 2017 | 1033 | 0.160 |
Why?
|
| Wearable Electronic Devices | 1 | 2021 | 76 | 0.160 |
Why?
|
| London | 1 | 2020 | 13 | 0.160 |
Why?
|
| Diet, Western | 1 | 2020 | 9 | 0.160 |
Why?
|
| Predictive Value of Tests | 3 | 2017 | 1104 | 0.160 |
Why?
|
| Anthropometry | 3 | 2015 | 85 | 0.160 |
Why?
|
| Health Personnel | 1 | 2024 | 385 | 0.160 |
Why?
|
| Swimming | 1 | 2019 | 30 | 0.150 |
Why?
|
| Risk | 1 | 2020 | 376 | 0.150 |
Why?
|
| Craniocerebral Trauma | 2 | 2010 | 56 | 0.150 |
Why?
|
| Head Protective Devices | 2 | 2010 | 19 | 0.150 |
Why?
|
| Weight Reduction Programs | 1 | 2019 | 62 | 0.150 |
Why?
|
| Organ Size | 2 | 2021 | 173 | 0.140 |
Why?
|
| Telomere Shortening | 1 | 2018 | 9 | 0.140 |
Why?
|
| Random Allocation | 1 | 2019 | 200 | 0.140 |
Why?
|
| Cancellous Bone | 1 | 2018 | 4 | 0.140 |
Why?
|
| Leukocytes | 1 | 2018 | 105 | 0.140 |
Why?
|
| Disability Evaluation | 2 | 2018 | 216 | 0.140 |
Why?
|
| Proteoglycans | 1 | 2018 | 35 | 0.140 |
Why?
|
| Child | 3 | 2022 | 4598 | 0.130 |
Why?
|
| Mobility Limitation | 1 | 2018 | 49 | 0.130 |
Why?
|
| Area Under Curve | 1 | 2017 | 149 | 0.130 |
Why?
|
| Exercise Tolerance | 1 | 2018 | 84 | 0.130 |
Why?
|
| Physical Education and Training | 1 | 2017 | 29 | 0.130 |
Why?
|
| Aged, 80 and over | 5 | 2018 | 5565 | 0.130 |
Why?
|
| Sweden | 1 | 2017 | 63 | 0.130 |
Why?
|
| Triamcinolone Acetonide | 1 | 2017 | 14 | 0.130 |
Why?
|
| Clinical Protocols | 2 | 2015 | 134 | 0.130 |
Why?
|
| Motor Activity | 3 | 2015 | 347 | 0.130 |
Why?
|
| Glycation End Products, Advanced | 1 | 2017 | 19 | 0.130 |
Why?
|
| Meniscus | 1 | 2016 | 3 | 0.130 |
Why?
|
| Mentoring | 1 | 2017 | 62 | 0.120 |
Why?
|
| Antirheumatic Agents | 1 | 2018 | 227 | 0.120 |
Why?
|
| Dietary Fats | 1 | 2017 | 178 | 0.120 |
Why?
|
| Fractures, Bone | 1 | 2017 | 138 | 0.120 |
Why?
|
| Actigraphy | 1 | 2016 | 51 | 0.120 |
Why?
|
| Wrestling | 1 | 2015 | 2 | 0.110 |
Why?
|
| Weight Lifting | 1 | 2015 | 13 | 0.110 |
Why?
|
| Blood Pressure | 1 | 2017 | 525 | 0.110 |
Why?
|
| Patient Compliance | 1 | 2017 | 365 | 0.110 |
Why?
|
| Randomized Controlled Trials as Topic | 4 | 2019 | 798 | 0.110 |
Why?
|
| Data Collection | 1 | 2015 | 381 | 0.110 |
Why?
|
| Vitamin D Deficiency | 1 | 2014 | 42 | 0.110 |
Why?
|
| Milk | 1 | 2014 | 47 | 0.100 |
Why?
|
| Cadaver | 1 | 2014 | 127 | 0.100 |
Why?
|
| Obesity | 2 | 2019 | 1263 | 0.100 |
Why?
|
| Wounds and Injuries | 1 | 2016 | 255 | 0.100 |
Why?
|
| Disease Management | 1 | 2015 | 233 | 0.100 |
Why?
|
| Pilot Projects | 3 | 2011 | 1002 | 0.100 |
Why?
|
| Biomechanical Phenomena | 4 | 2017 | 282 | 0.100 |
Why?
|
| Sample Size | 3 | 2018 | 66 | 0.100 |
Why?
|
| Analysis of Variance | 3 | 2010 | 604 | 0.090 |
Why?
|
| Philadelphia | 1 | 2012 | 24 | 0.090 |
Why?
|
| Urban Health | 1 | 2012 | 40 | 0.090 |
Why?
|
| Outpatient Clinics, Hospital | 1 | 2012 | 38 | 0.090 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2014 | 297 | 0.090 |
Why?
|
| Clinical Trials as Topic | 1 | 2015 | 460 | 0.090 |
Why?
|
| Hypertension | 1 | 2017 | 609 | 0.090 |
Why?
|
| Microcomputers | 1 | 2011 | 7 | 0.090 |
Why?
|
| Exercise Test | 1 | 2013 | 256 | 0.090 |
Why?
|
| Comorbidity | 1 | 2015 | 1115 | 0.090 |
Why?
|
| Computers, Handheld | 1 | 2011 | 37 | 0.090 |
Why?
|
| Procollagen | 1 | 2011 | 11 | 0.090 |
Why?
|
| Electromyography | 2 | 2008 | 98 | 0.090 |
Why?
|
| Chondrocytes | 1 | 2011 | 45 | 0.080 |
Why?
|
| Practice Guidelines as Topic | 1 | 2015 | 727 | 0.080 |
Why?
|
| Drug Prescriptions | 1 | 2012 | 164 | 0.080 |
Why?
|
| Drug Therapy, Combination | 1 | 2012 | 461 | 0.080 |
Why?
|
| User-Computer Interface | 1 | 2011 | 125 | 0.080 |
Why?
|
| Smoking | 1 | 2015 | 860 | 0.080 |
Why?
|
| Medication Adherence | 1 | 2012 | 198 | 0.080 |
Why?
|
| Animals | 3 | 2022 | 21309 | 0.080 |
Why?
|
| Brain Concussion | 1 | 2011 | 37 | 0.080 |
Why?
|
| Apolipoproteins E | 1 | 2010 | 113 | 0.080 |
Why?
|
| Racquet Sports | 1 | 2010 | 4 | 0.080 |
Why?
|
| Socioeconomic Factors | 3 | 2017 | 797 | 0.080 |
Why?
|
| Text Messaging | 1 | 2011 | 95 | 0.080 |
Why?
|
| Interviews as Topic | 1 | 2012 | 529 | 0.080 |
Why?
|
| Joints | 1 | 2009 | 33 | 0.080 |
Why?
|
| Bayes Theorem | 2 | 2022 | 125 | 0.080 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2011 | 623 | 0.080 |
Why?
|
| Precision Medicine | 1 | 2010 | 127 | 0.070 |
Why?
|
| Registries | 2 | 2024 | 898 | 0.070 |
Why?
|
| Sex Factors | 3 | 2024 | 989 | 0.070 |
Why?
|
| Spinal Cord Injuries | 1 | 2010 | 54 | 0.070 |
Why?
|
| Multivariate Analysis | 3 | 2019 | 929 | 0.070 |
Why?
|
| Peptide Fragments | 1 | 2011 | 416 | 0.070 |
Why?
|
| Patient Satisfaction | 1 | 2012 | 433 | 0.070 |
Why?
|
| Students | 1 | 2011 | 226 | 0.070 |
Why?
|
| Thrombospondin 1 | 1 | 2008 | 7 | 0.070 |
Why?
|
| Cervical Vertebrae | 1 | 2010 | 120 | 0.070 |
Why?
|
| Acceleration | 1 | 2008 | 35 | 0.070 |
Why?
|
| Scapula | 1 | 2008 | 10 | 0.070 |
Why?
|
| Genetic Variation | 1 | 2010 | 391 | 0.070 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2011 | 605 | 0.070 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2011 | 508 | 0.070 |
Why?
|
| Head | 1 | 2008 | 56 | 0.070 |
Why?
|
| Shoulder Joint | 1 | 2008 | 30 | 0.070 |
Why?
|
| Stress, Mechanical | 1 | 2008 | 112 | 0.070 |
Why?
|
| Databases, Factual | 3 | 2018 | 884 | 0.070 |
Why?
|
| Myofascial Pain Syndromes | 1 | 2007 | 4 | 0.070 |
Why?
|
| Transforming Growth Factor beta | 1 | 2008 | 182 | 0.070 |
Why?
|
| Galvanic Skin Response | 1 | 2007 | 25 | 0.070 |
Why?
|
| Membrane Potentials | 1 | 2007 | 138 | 0.070 |
Why?
|
| Inflammation Mediators | 1 | 2008 | 181 | 0.060 |
Why?
|
| Rats | 1 | 2011 | 1996 | 0.060 |
Why?
|
| Postoperative Complications | 1 | 2014 | 1311 | 0.060 |
Why?
|
| Comparative Effectiveness Research | 2 | 2018 | 45 | 0.060 |
Why?
|
| Research Design | 2 | 2021 | 583 | 0.060 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2012 | 768 | 0.060 |
Why?
|
| Symptom Assessment | 2 | 2018 | 49 | 0.060 |
Why?
|
| Chi-Square Distribution | 2 | 2018 | 414 | 0.060 |
Why?
|
| Aggrecans | 2 | 2016 | 8 | 0.060 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2014 | 1656 | 0.060 |
Why?
|
| Feasibility Studies | 2 | 2021 | 579 | 0.060 |
Why?
|
| Metabolomics | 1 | 2026 | 59 | 0.060 |
Why?
|
| New Zealand | 1 | 2024 | 44 | 0.060 |
Why?
|
| Trauma Severity Indices | 2 | 2017 | 34 | 0.050 |
Why?
|
| Metacarpal Bones | 1 | 2024 | 4 | 0.050 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2008 | 346 | 0.050 |
Why?
|
| Interleukin-7 | 1 | 2024 | 29 | 0.050 |
Why?
|
| Minocycline | 1 | 2023 | 28 | 0.050 |
Why?
|
| Doxycycline | 1 | 2023 | 47 | 0.050 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2022 | 22 | 0.050 |
Why?
|
| Capsaicin | 1 | 2022 | 19 | 0.050 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2023 | 277 | 0.050 |
Why?
|
| Acetaminophen | 1 | 2022 | 52 | 0.050 |
Why?
|
| Phthalic Acids | 1 | 2022 | 41 | 0.050 |
Why?
|
| Consensus | 1 | 2023 | 181 | 0.040 |
Why?
|
| Patient Acuity | 1 | 2021 | 19 | 0.040 |
Why?
|
| Pharmaceutical Preparations | 1 | 2022 | 120 | 0.040 |
Why?
|
| Nutrition Surveys | 1 | 2022 | 146 | 0.040 |
Why?
|
| Fitness Trackers | 1 | 2021 | 20 | 0.040 |
Why?
|
| Preoperative Period | 1 | 2021 | 67 | 0.040 |
Why?
|
| Asymptomatic Diseases | 1 | 2021 | 50 | 0.040 |
Why?
|
| Ontario | 1 | 2021 | 45 | 0.040 |
Why?
|
| Postoperative Period | 1 | 2021 | 130 | 0.040 |
Why?
|
| Boston | 1 | 2021 | 257 | 0.040 |
Why?
|
| Goals | 1 | 2021 | 95 | 0.040 |
Why?
|
| Alcohol Drinking | 1 | 2022 | 322 | 0.040 |
Why?
|
| Patient Selection | 1 | 2021 | 483 | 0.040 |
Why?
|
| Genotype | 2 | 2011 | 670 | 0.040 |
Why?
|
| Arthrography | 1 | 2018 | 7 | 0.040 |
Why?
|
| Telomere | 1 | 2018 | 58 | 0.030 |
Why?
|
| Phenotype | 1 | 2022 | 1231 | 0.030 |
Why?
|
| Patellar Ligament | 1 | 2018 | 7 | 0.030 |
Why?
|
| Autografts | 1 | 2018 | 9 | 0.030 |
Why?
|
| X-Rays | 1 | 2018 | 46 | 0.030 |
Why?
|
| Sound | 1 | 2017 | 8 | 0.030 |
Why?
|
| Sleep | 1 | 2021 | 241 | 0.030 |
Why?
|
| Statistics, Nonparametric | 1 | 2018 | 214 | 0.030 |
Why?
|
| Drug Substitution | 1 | 2017 | 40 | 0.030 |
Why?
|
| Anti-Bacterial Agents | 1 | 2023 | 801 | 0.030 |
Why?
|
| Postural Balance | 1 | 2018 | 67 | 0.030 |
Why?
|
| Fatty Acids, Monounsaturated | 1 | 2017 | 17 | 0.030 |
Why?
|
| Protective Factors | 1 | 2017 | 33 | 0.030 |
Why?
|
| Systole | 1 | 2017 | 110 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2017 | 295 | 0.030 |
Why?
|
| Matrix Metalloproteinase 13 | 1 | 2016 | 8 | 0.030 |
Why?
|
| Cartilage Oligomeric Matrix Protein | 1 | 2016 | 3 | 0.030 |
Why?
|
| Risk Reduction Behavior | 1 | 2017 | 121 | 0.030 |
Why?
|
| Rupture | 1 | 2015 | 24 | 0.030 |
Why?
|
| Drug Utilization | 1 | 2017 | 204 | 0.030 |
Why?
|
| Optical Imaging | 1 | 2017 | 77 | 0.030 |
Why?
|
| Antihypertensive Agents | 1 | 2017 | 178 | 0.030 |
Why?
|
| Mental Health | 1 | 2019 | 360 | 0.030 |
Why?
|
| Accelerometry | 1 | 2016 | 64 | 0.030 |
Why?
|
| Calcium-Binding Proteins | 1 | 2015 | 94 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2017 | 740 | 0.030 |
Why?
|
| Academic Medical Centers | 1 | 2017 | 304 | 0.030 |
Why?
|
| Health Surveys | 1 | 2016 | 317 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2017 | 734 | 0.030 |
Why?
|
| Global Health | 1 | 2016 | 180 | 0.030 |
Why?
|
| Interleukin-1beta | 1 | 2016 | 273 | 0.030 |
Why?
|
| Parathyroid Hormone | 1 | 2014 | 44 | 0.030 |
Why?
|
| Observer Variation | 1 | 2014 | 215 | 0.030 |
Why?
|
| Activities of Daily Living | 1 | 2016 | 293 | 0.030 |
Why?
|
| Vitamin D | 1 | 2014 | 139 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 1 | 2014 | 315 | 0.020 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2014 | 187 | 0.020 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-2 | 1 | 2011 | 5 | 0.020 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-1 | 1 | 2011 | 8 | 0.020 |
Why?
|
| Matrix Metalloproteinase 3 | 1 | 2011 | 6 | 0.020 |
Why?
|
| Exudates and Transudates | 1 | 2011 | 12 | 0.020 |
Why?
|
| Interleukin-10 | 1 | 2011 | 163 | 0.020 |
Why?
|
| Checklist | 1 | 2011 | 69 | 0.020 |
Why?
|
| Immobilization | 1 | 2010 | 14 | 0.020 |
Why?
|
| Sports Medicine | 1 | 2010 | 26 | 0.020 |
Why?
|
| Alleles | 1 | 2010 | 452 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 1 | 2010 | 413 | 0.020 |
Why?
|
| Isometric Contraction | 1 | 2008 | 46 | 0.020 |
Why?
|
| Health Status Indicators | 1 | 2008 | 94 | 0.020 |
Why?
|
| Pain Threshold | 1 | 2007 | 21 | 0.020 |
Why?
|
| Movement | 1 | 2008 | 163 | 0.020 |
Why?
|
| Emergency Medical Services | 1 | 2010 | 258 | 0.020 |
Why?
|
| Brain | 1 | 2011 | 1594 | 0.010 |
Why?
|